McKechnie Duncan reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, reported two equity awards on January 22, 2026, receiving 4,720 and 2,080 shares of common stock at no cash price as earned performance-based stock units. Context notes these shares arise from 2023 and 2025 performance stock unit awards, with performance certified on January 22, 2026 and vesting scheduled in February 2026. Following these grants, he directly holds 22,938 Vertex shares.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported the grant of 9,012 shares of common stock on January 22, 2026. The shares were acquired at a price of $0 as earned performance shares from a performance stock unit award originally granted on February 12, 2025, which was subject to performance-vesting conditions.
The company’s management development and compensation committee certified the level of performance-goal attainment on January 22, 2026, and these shares are scheduled to vest on February 24, 2026. Following this grant, Leiden beneficially owns 33,039 shares of Vertex common stock directly, plus 440 additional shares held indirectly through a 401(k) plan.
Vertex Pharmaceuticals CEO and President Reshma Kewalramani reported two stock acquisitions tied to performance awards. On 01/22/2026, she acquired 26,972 shares of common stock at $0, representing earned performance shares from a performance stock unit award granted on 02/01/2023 after the compensation committee certified performance-goal attainment. These shares will vest on 02/13/2026, bringing her direct holdings to 142,940 shares.
On the same date, she acquired 11,885 additional common shares at $0 as earned performance shares from a separate performance stock unit award granted on 02/12/2025, also following committee certification of performance-goal attainment. These shares will vest in installments beginning on 02/24/2026, increasing her directly held common stock to 154,825 shares.
Vertex Pharmaceuticals executive vice president and CMO Carmen Bozic reported two stock award acquisitions of common stock on 01/22/2026. The filings show grant/award acquisitions of 7,866 and 3,467 shares. Footnotes describe these as earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, after the management development and compensation committee certified performance-goal attainment on 01/22/2026, with vesting dates in February 2026. After these awards, she directly holds 44,002 Vertex shares.
Vertex Pharmaceuticals executive Jonathan Biller reported the acquisition of 9,068 shares of common stock through earned performance awards. On 01/22/2026, he received 6,294 shares tied to a performance stock unit grant from 02/01/2023 and 2,774 shares tied to a grant from 02/12/2025, both at a price of $0 per share. The company’s management development and compensation committee certified performance attainment on 01/22/2026. The first block of shares is scheduled to vest on 02/13/2026, and the second will vest in installments beginning on 02/24/2026. Following these awards, Biller directly beneficially owns 24,374 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.
The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards. On 01/22/2026, Ambrose acquired 2,950 shares of Vertex common stock at $0 per share from an earned performance stock unit award originally granted on 02/01/2023, increasing direct holdings to 10,795 shares.
On the same date, Ambrose also acquired 1,300 additional shares at $0 per share from a separate performance stock unit award granted on 02/12/2025, bringing direct ownership to 12,095 shares. The filing explains that these are earned performance shares following the compensation committee’s certification of performance-goal attainment on 01/22/2026, with the related shares scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive David Altshuler reported stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,328 shares, each at a price of $0 per share, reflecting earned performance shares from prior performance stock unit awards. These awards were originally granted on 02/01/2023 and 02/12/2025 and included performance-vesting requirements that the company’s management development and compensation committee certified as achieved on 01/22/2026. After these transactions, Altshuler directly owned 34,477 shares of Vertex common stock. The 7,866-share portion is scheduled to vest on 02/13/2026, and the 3,328-share portion will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals director Suketu Upadhyay reported an acquisition of derivative equity on Form 4. On 01/15/2026, he acquired 80.316 deferred stock units at a price of $443.56 per unit, bringing his total holdings of these derivative securities to 2,718.648 units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock upon the earliest of Mr. Upadhyay’s termination from the board, a change of control of the company, or his disability or death. This filing reflects a change in his deferred equity position rather than an immediate cash transaction in Vertex common shares.
Vertex Pharmaceuticals director Bruce I. Sachs reported an automatic grant of deferred stock units tied to his board service. On January 15, 2026, he acquired 107.088 deferred stock units at a reference price of $443.56 per unit, bringing his total to 15,564.521 deferred stock units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock at the earliest of Sachs leaving the board, a change of control of the company, or his disability or death. This filing reflects equity-based compensation rather than an open-market stock purchase or sale.